C-YGSXMagnitude Biosciences
C. elegans, whole-organism HTS, automated imaging
research tools
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YGSX
C-YGSXC-YGSXC. elegans, whole-organism HTS, automated imaging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Getting Taken to School: Key Considerations and Differentiators of why “Academic” Transactions Have Typically Lower Deal Values than Industry Transact LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn … ce universities and research institutions do not have a realistic capability to fund the further development themselves or true minimum hurdle requirements for a deal, the lack of a real BATNA depresses the transaction values the Technology Transfer Offices can generate. 4. Equity is a real value driver that is not captured in transaction value Another element we noted in our analysis was that the size of the counterparty in the transaction matters. In the Industry Trans … ream Job is Hiding Within Your Dream Job Medpace 3y AstraZeneca Pharmaceuticals Scholarship Recipient Linara N. Welte Shares Her Pursuits in Medicine National Merit Scholarship Corporation 3mo 12 Breakthrough Biotech Inventions and the Patents that Cover Them John Storella 5y Conscience: Reshaping Drug Discovery in the Age of Open Science and AI CUBEC 1y The Path to “Full Self-Driving” in Clinical Operations Michelle Longmire M.D. 4mo HiRO: Just One of the Heroes in Clinical
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Skip to main content Issuu Search Read Features Flipbooks Transform any piece of content into a page-turning experience. Fullscreen Sharing Deliver a distraction-free reading experience with a simple link. Embed Host your publication on your website or blog with just a few clicks. Articles Get discovered by sharing your best content as bite-sized articles. Statistics Make data-driven decisions to drive reader engagement, subscriptions, and campaigns. Teams Enable groups of users to work together to streamline your digital publishing. Social Posts Create on-brand social posts and Articles in mi
William Haseltine, a longtime... - Insider International Facebook Log In Insider International's Post Insider International Verified account November 9, 2020 · Shared with Public William Haseltine, a longtime biotech executive, said that while this was "very welcome news," he also wants to see the data. businessinsider.com Why a top infectious-disease expert says it's too soon to celebrate Pfizer's coronavirus vaccine All reactions: 1 1 comment Like Comment Most relevant
Pharma Integrates 2024 - Life Science Integrates Sign up to our newsletter here Sign up to our newsletter here Our Events Pharma Sustainability Integrates FemHealth Integrates Advanced Therapies Integrates North Bio Integrates HealthTech Integrates PharmaTech Integrates Pharma Integrates Advanced Therapies Integrates About us Life Science Intelligence LSI Connect Sponsor Enquiry Contact Event Summary Pharma Integrates 2024 Connect with Pharma and Healthcare leaders pioneering change 2025 date announced: 13th November 2025 EVENT TOPICS: Track 1: Big Health Issues & Enablers Track 2: Technology … , as well as Board Member of the biotechnology company, BioNTech and investment fund RTW Biotech Opportunities. Nicola is also a member of the House of Lords, the Oxford Harrington Rare Disease Centre Advisory Board and the Royal Society Science Policy Expert Advisory Committee. Nicola served as a Minister in the Department for Health and Social Care under two Prime Ministers. As Minister for Innovation, she led on Life Sciences, NHS Data and Digital Transformation, and Globa … gs a breadth of therapeutic experience. With initial training provided from the award of the prestigious Royal Society of Edinburgh Enterprise Fellowship enabling transition from lab bench to boardroom, Suzy has founded services companies as well as therapeutic development companies as independent companies, joint ventures and multiple group subsidiaries as part of strategic corporate activity. Serving as CEO of AIM-listed biotech ValiRx for four years demonstrated her broad … across East, Southern and West Africa including the Africa Enterprise Challenge Fund and the Strategic Climate Institutions Programme in Ethiopia. Her experience includes TCFD, EU Taxonomy, SASB, GRI, ICMA Green Bond Principles, IFC OPIM Principles. Paul Wann | Emerson UK & Ireland X Paul Wann Emerson UK & Ireland Business Director, Sustainability & Decarbonisation Paul has worked in the process manufacturing industry since graduating as an Electrical Engineer from Brunel Uni … affairs? – what regulatory framework do we need to support the effective application of AI? What are the risks and opportunities? – how do we organise for success? Facilitated by Martino Picardo RS Therapeutics Chairman X Martino Picardo RS Therapeutics Chairman Martino is Chairman of RS Therapeutics and an Independent Consultant, ba
Work Groups - ELRIG About Who We Are Our legacy The Team Work Groups Policies Press Releases Exhibitors Community Awards Early Career Professionals Content Hub Contact Us Events Work Groups ELRIG’s work groups, led by field experts and guided by the board, focus on key initiatives like early career support, science programming, and strategy to effectively serve the life science community. Scientific Programme Sponsor Strategy Early Career Professionals Engagement Strategy Sustainability People & Culture Innovation Awards Scientific Programme Work Group Key objectives Assess areas of scient
Demeetra AgBio | Precise Gene Editing & Unlimited Opportunities | Christian Cummings LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn … ion is to enable innovation by providing clear, responsible access to the Nobel Prize–winning CRISPR/Cas9 patents. In a field moving as rapidly as gene editing, the surest way to accelerate is to de-risk early. Clarity on licensing is not bureaucracy; it is the infrastructure that allows science to scale. Explore how ERS can help your organisation gain licensed access to CRISPR/Ca9: https://lnkd.in/e8ykt89k #CRISPR #Innovation #IP 6 Like Comment Share Copy LinkedIn Facebook X … (ABFE) in the absence of experimental crystal structures, making it possible to apply gold-standard, physics-based free energy calculations much earlier in the drug discovery process. On Oct. 29, learn more about how Boltz-2 was developed, how it has evolved, and how it is being applied to Recursion’s AI-enabled drug discovery platform at Genetic Engineering & Biotechnology News ’ State of AI in Drug Discovery free virtual event. Najat Khan, PhD , Chief R&D Officer an
Our biggest and best yet! - BSRA Annual Scientific Meeting 2025 - BSRA Skip to content Menu Menu HOME About us Vision History Governance and Policy Board of Trustees Scientific Advisory Board About Ageing Membership Benefits Join Member Area Events 2026 Academic Seminar Series 2026 Public Lecture Series 75th Annual Scientific Meeting of the BSRA (2026): The Biology of Ageing All Events Annual Scientific Meeting Archive (2000-) Annual Scientific Meeting About Register Conference Venue View Programme and Speakers Sponsor/Exhibitor Application Conference Dinner Location Accommodation in Oxford El … thorisation (ETA) Instructions for presenters Sponsor/Exhibitor List Awards and Grant Funding Funding Calls Previous grant winners Lord Cohen Medal Annual Awards Conference Awards Hall of Fame Support Us Support Us Legacies Acknowledge Us News Contact us Donate Log in Our biggest and best yet! – BSRA Annual Scientific Meeting 2025 October 31, 2025 Category: Events , Funding , Industry , Korenchevsky , News , Uncategorized 200 delegates from across the ageing research fi … red here, left) of the University of Oxford for receiving the 2025 Korenchevsky Prize. ere eligible for our prestigious Korenchevsky Prize . Awarded to the best oral presentation, it includes a trip to the next AMERICAN AGING ASSOCIATION annual scientific meeting and an oral presentation slot there, allowing the BSRA to platform the science from future leaders in our field to the widest audience possible. Congratulations to Loren Kell of University of Oxford whose superb pres … tion of Research , at the end of which Early Career Researchers were invited to submit their pitch, with the winners given the opportunity to work up their proposal and pitch it to investors at next year’s ASM. The programme included two thought-provoking panel discussions on ‘Industry Insights into Emerging Nutraceuticals’, and ‘Ageing Research in the Public Eye.’ This second panel provoked lively debate from our panellists drawn from the media, communications, the charity s
PK!��k��[Content_Types].xml �(�̗]o�0����oQ�v���.���I�[�>i-�٧���9I�h��t�BvS)��� �kV�����i�_[�e�'�T�̉��+���QB=�o���-M� �+�04�߸��rrk�2�?戧+K-����|pb�57Uލ�������Ft槩�F0W��8K��B� �}�d��p�"NiP��S52��%��SM�=!U���R���m��?���'�p�5�/��PK!��L~��� word/document.xml�}ێ�H������E�َ�AS �X�^w�p��1W ��LqL�j��t�Uc�b�٫�ݧ�G�'����1���D�����` �����ǿ��Q��Eyg�/��[�J��~6���_^��-xc�Ҋ2La���/� ��տ~����_����d��&�H�����/��e9~��]� F��x;��yVd7��~6z�������}�����k�g��(���0� �Wus� �Z��x����a^F?�m��a�w��� ���)�sS�;�գ����z�ۯ�5�3�k� ����%ً/9|�/�(nJb�hB �* �h����UP�����
%PDF-1.6 %���� 1495 0 obj > endobj 1528 0 obj >/Filter/FlateDecode/ID[ ]/Index[1495 66]/Info 1494 0 R/Length 140/Prev 10853425/Root 1496 0 R/Size 1561/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"�$�I0[ Dr���. �ILf�I �x�-&��I^$0�L���� ��D���H�6)�DjIF�E`���b��s@$�>�� >stream h��}Pwǟ�MBBI���jb%g�R��5�K��vB �Z`���� �Z��`řH}���/h}��� -�)�7�'M v쩵R�+�^�v7�z7ӛ�����$���{���ͳ;� (uC@h!H��Cl*�n��ϧ�$�In�!+B F��U,�(�D�J����z���vS����>�o� �V��TJh���V��)c�I��y��C9�vA���ēx�y��7�ة���?;&; G���J�=i� [��f�|��U��m��xC�z7_��=�u���}���.3��]�=�[Szq����v�c���� [vO�e� … }yn-6���{�wz`����֜a�����7������ '_ pV�� endstream endobj 1523 0 obj >stream application/postscript Greg Nielsen SBT-Logo-TM-4c-pos.eps Adobe Illustrator CS2 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 uuid:24EBF3E16E8511DA9E4086E538E29E18 uuid:24EBF3E26E8511DA9E4086E538E29E18 endstream endobj 1524 0 obj >>>/Subtype/Form/Type/XObject>>stream H�2P��*�2PAC�l.}�`��b.#=Cs#=#s csC= ] ��H�(�+�+� �n� endstream endobj 1525 0 obj >/ProcSe … ����J�`� �L|0�@��#���24��[w���AX������ �u� endstream endobj 3 0 obj >stream application/pdf LONZA_LOGO_MAIN-BLK 2021-01-28T18:30:46Z 2021-01-28T18:30:46Z 2021-01-28T18:30:46+01:00 Adobe Illustrator 25.1 (Windows) uuid:a3de2334-99ae-43ee-9bbd-741f79caa74a xmp.did:4b30f76e-9211-bb47-ab33-a3600ddfe9ba uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9963990e-1bd9-b545-9ca6-06946215f430 xmp.did:9963990e-1bd9-b545-9ca6-06946215f430 uuid:5D20892493BFDB11914A8590D31508C8 … 6215f430 2021-01-28T18:06:09Z Adobe Illustrator 25.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4b30f76e-9211-bb47-ab33-a3600ddfe9ba 2021-01-28T18:13:17Z Adobe Illustrator 25.1 (Windows) / Print AIRobin Document False False 1 134.166337 51.249506 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 29 29 27 CMYK Red RGB PROCESS 227 6 19 CMYK Yellow RGB PROCESS 255 … ) 2024-01-31T09:39:48+01:00 2024-04-10T08:57:56+02:00 2024-04-10T08:57:56+02:00 application/vnd.adobe.photoshop 4 Coated FOGRA39 (ISO 12647-2:2004) xmp.iid:c6d133e2-6c37-4c43-a5c7-2d2003c911c9 adobe:docid:photoshop:cbdeaaad-f9b2-a14f-b3b0-3fa9427c4f33 xmp.did:31c8d117-0238-4925-9f3f-74244c25ee44 created xmp.iid:31c8d117-0238-4925-9f3f-74244c25ee4
How C. elegans assays can help with ageing population health | Magnitude Biosciences Ltd posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … n in Bala Gopalakrishnan 8mo Report this post This is a watershed moment in the application of AI in clinical trials in Canada providing win-win to patients, hospitals and pharmaceutical companies in accelerating adoption of new drugs and patient care solutions. It also validates the powerful AI engine built by Cardea Health Inc. for the medical domain. Naveed Ahmad - M.A., M.B.A. CEO and Co-Founder - Cardea Health Inc. - Clinical Trials, RWE, RWD, Implementation Science 8mo
Full Schedule Skip to main content Toggle navigation Login Search Home Tweets by SLAS2022 Icon Legend This session is not in your schedule. This session is in your schedule. Click again to remove it. Presentation Icons 2022 Innovation Award Finalist 2022 Additional Fee 2022 Live Stream 2022 On-Demand 2022 In-Person 2022 Tony B. Awardee 2022 Student Poster Reg Required Journal Author Full Schedule Home Full Schedule All Days Digital Only Exhibitor Tutorials Fri, Feb 4 Sat, Feb 5 Sun, Feb 6 Mon, Feb 7 Tue, Feb 8 Wed, Feb 9 Full Schedule Type here to filter the list Digital Only Exhibitor Tutoria … magnetic cell separation with DispenCell for gentle and simple T cell cloning - Application for immunotherapy Myriam Ben Khelil Sponsored By Roche Digital Only Exhibitor Tutorial: The AVENIO Edge System — Automated System for NGS Library Prep, Target Enrichment, QC, and Pooling Sponsored By Digital Only Exhibitor Tutorials Drop in to easier and faster automation with Big Kahuna and Junior Robin Sweeney Exhibitor Tutorial Sponsored By Test - Digital Only E … M East Coast USA Time Label free bioanalytical Technologies: Emerging Fields of Application Advances in Bioanalytics and Biomarkers 1:00 PM - 2:30 PM East Coast USA Time Label Free Bioanalytical Technologies: Emerging Fields of Application Advances in Bioanalytics and Biomarkers 1:00 PM - 1:30 PM East Coast USA Time MALDI Imaging in drug discovery Advances in Bioanalytics and Biomarkers 1:30 PM - 2:00 PM East Coast USA Time Unbiased high-throughput MALDI-TOF MS lipid and meta … bitor Tutorial Sponsored By 2:30 PM - 3:30 PM East Coast USA Time Ignite Award Finalist Presentations Ignite 2:30 PM - 3:30 PM East Coast USA Time Ignite Award Finalist Presentations Ignite Sponsored By 2:30 PM - 2:40 PM East Coast USA Time Ignite Award Finalist - Celldynamics ISRL Ignite 2:40 PM - 2:50 PM East Coast USA Time Ignite Award Finalist - BennuBio Ignite 2:50 PM - 3:00 PM East Coast USA Time Ignite Award Finalist - Celtarys Research Ignite 3:00 PM - 3 … inalist - Celtarys Research Ignite 3:00 PM - 3:10 PM East Coast USA Time Ignite Award Finalist - Magnitude Biosciences Ltd Ignite 3:10 PM - 3:20 PM East Coast USA Time Ignite Award Finalist - Partillion Bioscience Ignite 2:30 PM - 3:30 PM East Coast USA Time Poster Presentations: Session B 2:30 PM - 3:30 PM East Coast USA Time Poster Presentation
Northern Life Sciences Gathering Strengthens Collaboration | Northern Accelerator posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … ited Report this post We’re pleased to welcome Bradley McLean , PhD, to today’s Residency session at The Clinic, where he is leading a session on Intellectual Property & IP Strategy. As a Business Development Manager at the McMaster Industry Liaison Office (MILO) , Bradley supports the commercialization of health and life sciences research across McMaster University , Hamilton Health Sciences , and St. Joseph's Healthcare Hamilton . With a PhD in Biotechnology from The Un … lating discovery into protected, scalable innovation. Today’s session will help Residency participants better understand how to protect their ideas, navigate IP strategy, and position their ventures for long-term success. As the cohort moves closer to the Residency Pitch Finals, sessions like this help teams prepare to present strong, well-positioned ventures. 56 4 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 2,450 followers View Prof
Magnitude Biosciences - $950K Seed Stage Venture | Startup Intros Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Home / News / Magnitude Biosciences - Seed § Funding Ro
Oxford North proud to be Gold Sponsor of OBN’s BioTrinity 2025 | News | Oxford North About About Oxford North Masterplan ESG Engage Meet the team Location Overview Amenities Workspaces Offices & labs The Red Hall 1 & 2 Fallaize Street Phase 2 buildings VR tour Homes News Jobs Contact us news Labs Oxford North proud to be Gold Sponsor of OBN’s BioTrinity 2025 28/03/2025 For the third year running, Oxford North is proud to be a Gold Sponsor of BioTrinity 2025 , OBN’s flagship two-day conference for the life sciences industry, designed to catalyse growth for all who attend. This year’s ev
Northern Accelerator - 2026 Investor Profile, Portfolio & Investment Trends - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Invest … ort s Seed startups based in United Kingdom . Its latest investment was a $502K Grant (prize money) round in GlycoScoreDx on Apr 30, 2021 , which also saw participation from Northstar Ventures and Milltrust International Group . Key Metrics Founded Year 2016 Location North East England, United Kingdom Portfolio Companies Oak , Newcells Biotech & 7 more Sectors of Investment Enterprise Applications , Life Sciences & 4 more Stages of Investment Seed Locations of Investm … e Count : 80 as on Apr 30, 2026 Investors : Maven Capital Partners , North East Fund and 4 Other s Latest Funding Round : Series A, Jul 07, 2021 , $ ***** Highlight : Acquired 2 . Newcells Biotech Developer of induced pluripotent stem cells derived organoid models for research application. The company has developed a range of off-the-shelf iPSC-derived products and currently has neural progenitor cells and cardiomyocytes. In addition, it provides custom reprogramming and diff … Investors : Ukri , Maven Capital Partners and 10 Other s Latest Funding Round : Grant (prize money), May 27, 2025 , $ ***** Highlight : Editors' Pick 4 . Atelerix Atelerix has developed technology for storage of cells, especially for cryo shipping. The technology claims to provide following advantages Predictability and reliability in drug discovery models and for cells used as therapies, Customers can use cells and assays immediately on arrival, No need for cryopreserva … ound Details Round Amount Co-Investors Apr 30, 2021 GlycoScoreDx United Kingdom Grant (prize money) 7663 Northstar Ventures [+2] Apr 30, 2021 GlycoScoreDx United Kingdom Seed 6429 Northstar Ventures [+2] Nov 30, 2020 Gliff Technologies United Kingdom Seed 4347 North East Fund [+1] See more recent investments made by Northern Accelerator Acquired
We... - Federation of European Neuroscience Societies (FENS) Facebook Log In Federation of European Neuroscience Societies (FENS)'s Post Federation of European Neuroscience Societies (FENS) June 16 at 1:02 AM · Shared with Public We are proud to present #FENS2026 Silver sponsor: RWD Life Science! For over 20 years, RWD Life Science has been driving R&D innovation delivering cutting-edge solutions across: Neural research & imaging Animal surgery & modelling Cell/molecular biology Behavioural analysis Diagnostics & histopathology Learn more about them at www.rwdstco.com and
Northstar Ventures | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors Northstar Ventures Northstar Ventures Newcastle upon Tyne, England northstarventures.co.uk Overview Northstar Ventures is a venture capital firm that invests in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing. They provide expertise, experience and a powerful network to help their portfolio companies grow and achieve lasting impact. Y
Facebook Terokai perkara yang anda sangat suka . Log masuk ke Facebook E-mel atau nombor telefon mudah alih Kata laluan Log masuk Terlupa kata laluan? Cipta akaun baharu Bahasa Melayu English (US) فارسی العربية Türkçe Deutsch Français (France) Lebih banyak bahasa... Daftar Log Masuk Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Dasar Privasi Pusat Privasi Perihal Cipta Iklan Cipta Halaman Pembangun Kerjaya Kuki Pilihan Iklan Terma Bantuan Muat Naik Kenalan & Bukan Pengguna Meta © 2026
Global Venturing Global Venturing | Past Events Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More --> News People Analysis Dea … ies for investments SAP will commit 40% of the investable capital in its SAP.io Fund to support startups led by women and minorities, with a goal of backing at least 200 such companies within five years. Find Out More --> Jan 22, 2019 Parkwalk Advisors invests $81.7m in 2018 The IP Group-owned fund management unit closed three university funds targeting Cambridge, Oxford and Bristol-linked companies last year. Find Out More --> Jan 21, 2019 HighLife hits series B round The Li
--> UK C. elegans Meeting 2025 | Davies Lab top of page DAVIES LAB Home Research Lab members Join us Contact Publications UK Worm Meeting 2025 ECR Workshop 2025 More Use tab to navigate through the menu items. UK C. elegans Meeting 2025 3-4th April 2025 - Durham We are delighted to bring the Genetics Society-sponsored UK C. elegans Meeting to the centre of the UK (!) and host the 2025 meeting in Durham. In a modification to the normal format of the UK C. elegans Meeting, it will run from lunch on Thursday 3rd April until lunchtime on Friday 4th April, to allow for more time for interac
%PDF-1.5 %���� 2 0 obj > endobj 5 0 obj > stream x��R�N�0���9'�CH$jZQ�¥ ���koS��m�I�k �$~�m� �������d���C�5 �J�+��3��^F�������Ȩ�t6���� �@�����%3�v���=��㱄���Z �"���Rn��Œ�D�SD݅�R�꺎�ql˜ �$a��"dD�`o"���Vc^��t�kIq�rU�[!)h(�φ�ў�.� si7 [0|@��Ll �;���$J�jn���3`��9%'�|c����2�FZPAC�-�t��}E���V1�M$a�+ �t�s�B%�̕�B�}��r�&��*�=��*y��N�/���?�;|^c�.�� /.5��J��������o^N�� endstream endobj 16 0 obj > stream x����j�0 ໞB��ٲl BMF顇�]Gi�YI {�a/���}�����' /V22>��Y�8�E �\/��͘���94 �N��VU�E� �F��-��s�+�T��Hl�ш}N� ����?+�hWc� endstream endobj 18 0 obj > stream x��αj1 �]O��P
https://lnkd.in/eYrgx6YW #SpinOut #BiotechInnovation #CountyDurham"> https://lnkd.in/eYrgx6YW #SpinOut #BiotechInnovation #CountyDurham"> https://lnkd.in/eYrgx6YW #SpinOut #BiotechInnovation #CountyDurham"> Magnitude Biosciences CEO featured in N magazine for biotech success | The North East Technology Park - NETPark posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more i … th newsletter: https://lnkd.in/gJtEFuQg Evommune Files for IPO; Ascenta's $325M Fund ; Orbital Therapeutics ' Acquisition; Expedition Therapeutics Raises $165M #healthcare #biotech #lifescience #HealthTech #AI 3 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in San Francisco Biotech Networks 9,023 followers 8mo Report this post SFBN Feed: insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform
Latest Investment News | Maven Capital Partners | Finance Durham Fund Skip to content Investor Area Seek Investment Overview Management Buyout Growth Capital Regional Growth Funds About Our Regional Funds Finance Durham Fund IFS Maven Equity Finance MEIF II Debt Finance East and South East Midlands NPIF II Maven Equity Finance SWIF Maven Equity Finance Property Invest Overview Private Investor Co-investment About Maven Investor Partners Private Equity Investment Property Investment EIS About EIS Maven Cognition EIS VCTs About VCTs Current Offers Institutional Investor Buyout Fund Portfolio Abo … pital Property NPIF Maven Equity Finance MEIF Maven Debt Finance Finance Durham Fund North East Development Capital Fund SWIF Maven Equity Finance IFS Maven Equity Finance Year: All Years 2025 2024 2023 2022 2021 2020 2019 2018 2017 Older Posts All Years 2025 2024 2023 2022 2021 2020 2019 2018 2017 Older Posts Clear Filter Maven strengthens North East team with two new appointments Published: May 20, 2026 Category Tag: Growth Capital , NPIF Maven Equity Finance , Finance Durh … 2026 Category Tag: Growth Capital , NPIF Maven Equity Finance , Finance Durham Fund Read More Bdaily secures six-figure investment to fuel national expansion Published: May 13, 2026 Category Tag: Finance Durham Fund Read More Maven backs high-tech space communications firm aXenic Published: Oct 06, 2025 Category Tag: NPIF Maven Equity Finance , Finance Durham Fund Read More Maven backs specialist marketing company The Social Co. Published: Sep 29, 2025 Category Tag: Finance … ing company The Social Co. Published: Sep 29, 2025 Category Tag: Finance Durham Fund Read More Maven leads £1.625 million investment in Dyer Engineering Published: Aug 19, 2025 Category Tag: NPIF Maven Equity Finance , Finance Durham Fund Read More Maven backs Crafter’s Companion alongside founder Sara Davies Published: Aug 15, 2025 Category Tag: NPIF Maven Equity Finance , Finance Durham Fund Read More Maven leads investment in Magnitude Biosciences Published: May 27, 2025 C … ublished: May 27, 2025 Category Tag: NPIF Maven Equity Finance , Finance Durham Fund Read More Maven invests £750,000 in tech innovator PervasID Published: Nov 21, 2024 Category Tag: NPIF Maven Equity Finance , Finance Durham Fund Read More NPIF II Maven Equity Finance completes first deal Published: Oct 15, 2024 Category Tag: NPIF Maven Equity F
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Let the Worm Wiggle into the Pipeline: The Case for C. elegans in Modern Drug Discovery - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publi … AG. RNAi screens in Caenorhabditis elegans in a 96-well liquid format and their application to the systematic identification of genetic interactions. Nat Protoc. 2006 Aug;1(3):1617–20. Petrascheck M, Ye X, Buck LB. A high-throughput screen for chemicals that increase the lifespan of Caenorhabditis elegans. Ann N Y Acad Sci. 2009 Jul;1170:698–701. Roy PJ. Drug screens using the nematode Caenorhabditis elegans. Genetics. 2025 Aug 12;2
Vitafoods Europe 2026: Healthspan and Longevity Focus | Magnitude Biosciences Ltd posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
Magnitude Biosciences: Revolutionising Research Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoSca … exus and Orbit. In June 2023, it secured a Future Economy Investor Partnerships grant of almost £250,000 from Innovate UK, which was matched by an investment from the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures Limited. Fozia said the investment will help accelerate research and growth. “We expect to more than double the team in Sedgefield to 45 over the next two to three years, with a larger commercial tea … laborative research environments, which blend academic knowledge with practical application, play in fostering groundbreaking advancements in biotechnological innovation. The synergy between academia and industry provided by Durham University and CPI strengthens the foundation upon which pioneering biotechnological innovations can flourish." If you would like to find out more about locating your business at NETPark, get in touch or call 01740 625250 For more information on Ma
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Magnitude Biosciences secures over £700,000 to accelerate in vivo high-throughput drug discovery platform Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publication … inance, which is managed by Maven as part of the Northern Powerhouse Investment Fund II, the Finance Durham Fund, established by Durham County Council and overseen by Business Durham, as well as continued support from existing investors Northstar Ventures. The investment was matched with grant funding from Innovate UK through the Investor Partnerships: Digital Technologies North East programme. This funding will enable Magnitude Biosciences to enhance its proprietary WormGaze … s scale delivery, grow its team, and expand its impact on drug development. The grant funding was awarded under Innovate UK’s Investor Partnerships - Digital Technologies North East competition, which aims to connect ambitious UK businesses with aligned private capital. Magnitude Biosciences’ selection for the programme reflects the strategic importance of its work in enabling scalable, ethical, and cost-effective early-stage drug discovery. For more information on our HTS pl
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case S
Milner Newsletter: February 2026 Registration is open for the Milner Therapeutics Symposium View this email in your browser News@ Milner Registration for the 2026 Milner Therapeutics Symposium is now open! Milner Update: February 2026 It has been a busy start to the year at the Milner Institute, and we have already hosted two fantastic events for our affiliates and partners. We welcomed more than 45 affiliated companies to a business-to-business networking event , and also hosted the Cambridge-Oxford BioVenture Showcase . Thank you to everyone who contributed to making thes … re appropriate e.g. tool compounds, compound libraries Find out more and apply » Milner Research The Functional Genomics Screening Lab (FGSL) was recently awarded an OBN Award in the category of Most Impactful Industry Collaboration . The award recognises our efforts in driving academic-industry partnerships with the MRC and AstraZeneca to convert pioneering science into therapies by interrogating the genome at scale. To learn more about the FGSL … se and the use of gene editing to better understand how diseases arise, and the application of artificial intelligence and quantum computing to interrogate large patient and human tissue-based datasets. New publication alert! Our AI and Computational Research team are delighted to have published in NPJ Drug Discovery this week, entitled " A systems-level machine learning approach uncovers therapeutic targets in clear cell renal cell carcinoma ". Explore our resea … ; #21toWatch Company shortlist . Ignota Labs were shortlisted for a One Nucleus Award in the category of Best Use of Emerging Technology of the Year . Nikon BioImaging Lab won the prestigious Deshima Award in the “Newcomer” category and also launched their Illumination Program . OmicsChart have changed their name to Vedaly. The company helps biopharma integrate AI, data, and analytics directly into scientific and strategic decision-m … company’s Board of Directors, and were also shortlisted for a One Nucleus Award in the category of Best Therapeutic R&D Programme of the Year . ValiRx CEO Mark Eccleston spoke to DeciBio about endometriosis and precision medicine. VetorBuilder announced they will partner with Ikarovec to advance eye
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FA … 500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures Limited, and Saker Capital LLP. The Company’s earlier loans totalling £250,000 from the Government's Future Fund, Saker Capital and Northstar Ventures have also been converted as part of this investment round. The investment has been made in response to rapidly growing customer demand fo … ve happened without the continued support of our investors’. About Future Fund The Future Fund was established to support the UK’s innovative businesses currently affected by Covid-19. These businesses have been unable to access other government business support programmes, such as CBILS, because they are either pre-revenue or pre-profit and typically rely on equity investment. The Future Fund, now closed to new applications, provides eligible companies with convertible … esigned to convert into equity at the next qualifying funding round. The Future Fund is developed by the government and delivered by the British Business Bank. To find out how Magnitude Biosciences can support your research contact us via [email protected] Find out more Press Contact: Jessica Evans [email protected] Related Press Releases [gs_wpposts theme="gs_wppost_grid_1" cols="3" num="46" group=" press-release"] Scroll to Top
Ignite Award Join About Log In CONNECTED APPLIED Learning Search EVENTS Events Calendar Applied Liquid Handling Boot Camp SLAS Europe 2026 Conference and Exhibition SLAS2027 International Conference & Exhibition Boost Your Brand SLAS Ignite PUBLICATIONS SLAS Discovery SLAS Technology Electronic Laboratory Neighborhood Point-to-Point (P2P) e-newsletter MEMBERSHIP Membership Types and Benefits Member Directory SLAS Fellow Member Program Statement of Conduct EDUCATION Applied Liquid Handling Boot Camp SLAS Ignite APPLIED Online Learning Micro-Credentials Program New Matter Podcast Webinars Sh … SLAS2022 International Conference and Exhibition > Sponsor and Exhibit > Ignite Award Ignite Award --> --> Event Menu Relive SLAS2022 Content Learn Sponsor and Exhibit Exhibitor Floorplan SLAS2022 Sponsorship and Exhibitor Prospectus Exhibit & Sponsor Service Center Exhibitor Hotel & Travel Information Innovation AveNEW Ignite Award New Product Award New Product Launches 2022 Sponsors Online Media Center Safe Meeting Guidelines February 5-28, 2022 Boston C … -28, 2022 Boston Convention & Exhibition Center Boston, MA, USA Register Ignite Award The SLAS Ignite Award recognises the best start-up or emerging company exhibiting within Innovation Ave NEW , the specially designated area for start-ups and emerging companies within the Exhibition. Congratulations to the following five companies chosen to compete for the 2022 SLAS Ignite Award. Watch their presentations on-site or connect with them on the event platform. BennuBio (USA) -- … s. (See the technology that helped co-founder Joseph DeRutte win the Innovation Award at SLAS2020.) Companies selected for Innovation Ave NEW , and who opt-in to compete for the SLAS Ignite Award, will be judged by an SLAS panel on a combination of key concepts, including their marketing plan, market presence and potential, funding prospects, plan for growth and the existence of balanced company leadership, among other qualities, for a chance to win $5,000. Application and De … p, among other qualities, for a chance to win $5,000. Application and Deadlines Deadline for SLAS2022 Innovation Ave NEW Applicants — Monday, October 11 Announcement of SLAS2022 Innovation Ave NEW companies — Week of November 8 Deadline to Opt-In for the Ignite Award — Monday, November 29 Announcement of Ignite Award finalists &
Loading company information... Home Assistant Search Sponsored Jobs New Tools Learn FAQ News & Articles Sign in free Use Google, Microsoft or LinkedIn Product AI Assistant Sponsor Search Visa Calculator Immigration Guides News & Articles Legal Privacy Policy Terms of Service Editorial Policy Company About Contact Get the App Android (Google Play) Important Disclaimer ImmigrationGPT.co.uk is an independent AI-powered reference tool. We are not affiliated with the Home Office or any government body. This platform provides immigration information, not immigration advice. Under Section 84 … (years) 1 year 3 years 5 years Including partner? Number of children − 0 + Visa application fee £ 719 Health surcharge ( 3 years) £ 3,105 Certificate of Sponsorship £ 199 Estimated total cost £ 4,023 * Costs are estimates based on 2026 rates. Actual costs may vary. Ask AI about visa requirements Register History First Added Nov 25, 2025 Last Verified Jun 25, 2026 Active License Licensed Visa Route Skilled Worker Updated 1 day ago Check Your CV for This Company We'll pref … (years) 1 year 3 years 5 years Including partner? Number of children − 0 + Visa application fee £ 719 Health surcharge ( 3 years) £ 3,105 Certificate of Sponsorship £ 199 Estimated total cost £ 4,023 * Costs are estimates based on 2026 rates. Actual costs may vary. Ask AI about visa requirements Register History First Added Nov 25, 2025 Last Verified Jun 25, 2026 Active License Licensed Visa Route Skilled Worker Updated 1 day ago Check Your CV for This Company We'll pref
Magnitude Biosciences secures UK government Future Fund to expand its workforce - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications … s Contact News Press Release Magnitude Biosciences secures UK government Future Fund to expand its workforce Magnitude Biosciences 5 March 2021 Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs across the world are slowing down because of COVID-19 restrictions. Many companies and universities are turning increasingly to contract research organisations (CROs) to outsource their research. To meet this need, Magnitude Biosciences, a … RO in County Durham, has secured funding from the government Coronavirus Future Fund. The Coronavirus Future Fund invests in innovative UK companies to boost their activity during the pandemic. Current investors in Magnitude Biosciences, Saker Capital and North East Innovation Fund run by Northstar Ventures Capital, have matched the government funds. In total, £250,000 will be used to grow the company’s workforce and facilities at NETPark, a technology hub in Sedgefield. Magn … More information is available on www.magnitudebiosciences.com The Future Fund is an initiative from the UK government to support innovative businesses in the UK during the Covid-19 pandemic. More information is available on https://www.gov.uk/guidance/future-fund Northstar Ventures is one of the leading early stage investors in UK businesses, and actively mentor the companies they support, as well as providing financial backing. More information is av
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
Research Scientist (Full time / Permanent) at Magnitude Biosciences Ltd | Apply now! – StudySmarter – Talents Everything for your career For employers Find a job Research Scientist (Full time / Permanent) Apply Now Apply Now Job Board Companies Magnitude Biosciences Ltd Research Scientist (Full time / Permanent) Research Scientist (Full time / Permanent) Full-Time 28800 - 48000 £ / year (est.) No working from home possible Apply Now Apply Now We are seeking a full time, permanent, driven and passionate Research Scientist. This role offers an exciting opportunity to apply your research expertis … will be appropriate for the skills and experience of the successful candidate. Deadline: 24 December 2024 We carefully review all applications and will contact shortlisted candidates for the next stages of the recruitment process. If you have not heard from us by January 2025, please kindly assume that your application has not been successful on this occasion. Applicants must have the right to work in the UK. Unfortunately, we are unable to provide visa sponsorship for this … into the company culture and expectations, which can be invaluable during your application process. ✨ Tip Number 3 Prepare to discuss your experience in a commercial lab setting. Be ready to share specific examples of how you've contributed to projects, particularly in terms of problem-solving and teamwork, as these are key aspects of the role. ✨ Tip Number 4 Stay updated on the latest advancements in molecular biology and assay development. Being knowledgeable about rec … Management Technical Writing Adaptability Strong Work Ethic Some tips for your application 🫡 Tailor Your CV: Make sure your CV highlights relevant experience and skills that align with the Research Scientist role. Emphasise your educational background, particularly if you have a BSc, MSc, or PhD in a relevant subject, and any experience with C. elegans or similar models. Craft a Compelling Cover Letter: Write a cover letter that showcases your passion for research and your … ntal data effectively in previous roles. Highlight Relevant Experience: In your application, focus on your experience working in a commercial lab environment. Detail any work you've done related to assay development, validation, or molecular biology, as these are key aspects of the role. Proofread Your Application: Before submitting, carefull
Global Visa Ally — Visa Sponsorship Jobs Worldwide Welcome to Global Visa Ally Note: This site uses JavaScript for the best user experience. For bots and crawlers, we provide static HTML versions of our pages below. Key Pages: About Global Visa Ally Premium Hub - All Tools Visa Job Search (40+ Countries) Course Finder (11,000+ Programs) Blog & Guides Visa News Updates Tourism & Travel Tools & Resources: CV Builder AI Document Writer Document Scanner Passport Photo Tool Embassy Locator Mock Interview Practice Translation Helper Travel Itinerary Builder For AI Training: Global Visa Ally is an AI
--> Magnitude Biosciences secures over £700,000 to accelerate in vivo high-throughput drug discovery platform top of page About NETPark NETPark People NETPark Companies Total Support Environment Funding & Finance Community Engagement Collaborative Networks Success Stories Locate Here Available Space Phase Three NETPark Plexus NETPark Explorer NETPark Discovery Meeting Rooms NETPark Virtual Office Services & Facilities Centre For Process Innovation (CPI) National Formulation Centre High Value Manufacturing Catapult Compound Semiconductor Apps Catapult Durham University Research Institut … ay 28, 2025 3 min read Maven leads investment alongside Northstar Ventures with grant funding from Innovate UK to drive development of next-generation drug screening platform. Magnitude Biosciences, a specialist contract research organisation (CRO) in County Durham offering in vivo discovery of treatments for age-related conditions and other diseases using C. elegans, has secured over £700,000 in combined funding to scale up its high-throughput screening (HTS) platform. The i … inance, which is managed by Maven as part of the Northern Powerhouse Investment Fund II, the Finance Durham Fund, established by Durham County Council and overseen by Business Durham, as well as continued support from existing investors Northstar Ventures. The investment was matched with grant funding from Innovate UK through the Investor Partnerships: Digital Technologies North East programme. This funding will enable Magnitude Biosciences to enhance its proprietary WormGaze … s scale delivery, grow its team, and expand its impact on drug development. The grant funding was awarded under Innovate UK’s Investor Partnerships - Digital Technologies North East competition, which aims to connect ambitious UK businesses with aligned private capital. Magnitude Biosciences’ selection for the programme reflects the strategic importance of its work in enabling scalable, ethical, and cost-effective early-stage drug discovery. Tags: Magnitude Bioscience Industr
MAGNITUDE BIOSCIENCES LIMITED filing history - Find and update company information - GOV.UK Cookies on Companies House services We use some essential cookies to make our services work. We'd also like to use analytics cookies so we can understand how you use our services and to make improvements. Accept analytics cookies Reject analytics cookies View cookies You've accepted analytics cookies. You can change your cookie settings at any time. Hide this message You've rejected analytics cookies. You can change your cookie settings at any time. Hide this message Cookies on Companies House services … ges (2 pages) 06 Dec 2022 PSC02 Notification of The Noth East (Erdf) Innovation Fund Limited Partnership as a person with significant control on 19 September 2019 View PDF Notification of The Noth East (Erdf) Innovation Fund Limited Partnership as a person with significant control on 19 September 2019 - link opens in a new window - 2 pages (2 pages) 05 Dec 2022 PSC09 Withdrawal of a person with significant control statement on 5 December 2022 View PDF Withdrawal of a person w
NETPark's Magnitude Biosciences gets funding from Maven North East | Sara Williams posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … nvested in Magnitude Biosciences Ltd through the Northern Powerhouse Investment Fund II and the Finance Durham Fund to support the development of its next generation drug screening platform. This funding will enable the team to scale their patented WormGazer® technology to screen thousands of compounds each week, accelerating discovery, cutting costs and reducing reliance on traditional testing models. Learn more about this latest North East investment👇 https://hubs.ly/Q03sd … ech Trust and this week’s Monday Manager, tells Portfolio Adviser why she chose fund management over a career in a science lab, discusses the health breakthroughs seen by portfolio companies and shares insights on M&A and drug pricing. Learn more: https://lnkd.in/evwur4y3 #PortfolioAdviser #MondayManager #Biotech #FundManagement 4 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Business Insight News Page 1,541 followers 8mo Report this post W … al Emergence 2026 Conference in Sydney in February. For High-Profile Investors, Fund Managers & Family Offices: 🤝 Gain exclusive, curated access to a pipeline of high-potential, investor-ready companies in a critical growth sector—Australia's life sciences industry. 🤝 Bridge the gap between world-class innovation and the private capital seeking deep-tech and future-focused opportunities. We are now accepting expressions of interest from companies that would like to part … ontinue with dog study whilst awaiting the first payment of the Wallonia region grant.” The company said the financing would provide essential working capital and tie investor returns to the group’s long-term performance through the attached warrants. http://dlvr.it/TNQQY6 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign
Magnitude Biosciences featured in The Times for health drug discovery | Durham University posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … #Entrepreneurship #ResearchToMarket #RIStartups #RIInnovation Slater Technology Fund 1,476 followers 9mo Edited 🎥 Innovation starts in the lab — but it reaches the world through partnerships. At the University of Rhode Island , the Ocean Technology Center is proving what’s possible when research meets entrepreneurship. This new incubator model is already launching companies like AUDIANCE, Inc. , a startup developing safer gel-based lithium batteries with applications in both … ealth & Human Performance 4,046 followers 9mo Edited Report this post A new fund at the #UFHHP aims to spark collaboration between healthcare industry partners and emerging entrepreneurs and innovators 💡. The Entrepreneurship & Translational Incubation Fund, launched by Camelot BioCapital , a venture platform focused on biotech company creation that was co-founded by UF graduate Colby Kash , D.C., M.S., will provide mentorship, resources and awards to innovators acro … UF 🧬🔬. 📰 Read more about the Entrepreneurship & Translational Incubation Fund by heading to this link: https://ow.ly/QKl250WVnBa #UF #Innovation #Entrepreneurship #UFAlumni | University of Florida Alumni Association 15 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Inceptigen Associates LLP 128 followers 9mo Report this post How COVID-19 Sparked an Entrepreneurial Spirit? The pandemic didn’t just strain hospitals — it transforme
Longevity Conferences | Preliminary data generated through a collaboration between contract research organisation Magnitude Biosciences and biotech investor and entrepreneur ...
%PDF-1.7 %���� 1 0 obj >/Metadata 1073 0 R/ViewerPreferences 1074 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 540 720] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��V�n�@}����5�ۖ�P�@*4�B&uR _������G�D����=gf����Uח�|����C���;X,��{.� ��������(]�Ϡ ��4W����fuLN�|QX8j�C�1"�� ^���? f Ƈ��!Ӛ �T*OU�I\���jg��H3Ď,�o z�^UD�b��jU@;�� L߆����h^ ˶�k`�]up�ַ���^>�ܩ���( ��L ���r��� Z�%ϔ�4�Y��R�3�P�k� ��a͎,�aQ��� �T���5�-~� '� ��U��(������@�D�($�,��aӝ�\�9� C���Wg�Q����� w�~-q ?H
#neuroscience #ageing #ai #vivoscantm #bio2026 #biotech #drugdiscovery #healthyageing #neuroscience #longevity #translationalscience | Magnitude Biosciences Ltd LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join
Ezcurra Lab – at University of Kent, Canterbury Skip to content Menu About us News Research In the media Publications People Funding Contact Blog Ezcurra Lab at University of Kent, Canterbury News May 2025: Congratulations to PhD student Laura Freeman for successfully defending her thesis during her viva! Great to be out celebrating in Canterbury with current and previous members, and friends, of the lab. April 2025: The Ezcurra and Tullet labs at the UK C. elegans meeting in Durham. Great to meet up fellow scientists and hear about recent research using the C. elegans model system. Octo … 8216;Guts are but roots inverted’. Laura, Marina and Feng attended a RANK Prize Symposium bringing together researchers studying host-microbe interactions in plants, animals and humans. Fanastic science and interdisciplinary interactions in the beautiful Lake District. August 2024: New preprint from the lab. Great to collaborate with our industrial partners Magnitude Biosciences and Perfectus Biomed on a project funded by National Biofilms Innovation Centre to develop n … r here . March 2024: Laura Freeman, PhD student in the lab, is awarded a travel grant by the American Aging Association. Amazing work Laura, congratulations! December 2023: Laura Freeman, PhD student in the lab, wins first prize at the Three minute PhD Thesis Competition at University of Kent. Excellent and funny presentation, congratulations Laura! November 2023: Mireya Vazquez-Prada is awarded her PhD. She passed her viva with flying colours! Mireya is the first PhD student … ns! September 2023: Congratulations to Laura Freeman for being awarded a travel grant from the British Society for Research on Ageing! This will enable Laura to attend the American Aging Association AGE scientific conference and present her PhD research. Well done Laura! August 2023: New funding to the Ezcurra Lab. Thank you to the MRC Impact Accelerator for funding our research! In collaboration with Dr Bradley Elliott and Dr Manuel Corpas at University of Westminster, we wi … oduction can be developed to upcycled foods that improve health. Learn more and apply here. Email Marina at [email protected] for more informal enquires. October 2022: Join us! PhD project available through the South Coast Biosciences Doctoral Training Programme: The Power of Plants and Nematodes – New sustainable approaches to tackle bi
Enterprise - News, analysis, advice - Business Live birminghampost Load mobile navigation Around The UK West Midlands East Midlands South West North West North East Yorkshire & Humber South East East London Northern Ireland Wales Scotland Expand Sectors Enterprise Professional Services Retail & Consumer Economic Development Tech Commercial Property Manufacturing Ports & Logistics Law Finance Expand Climate Opinion Partner Stories SUBSCRIBE PREMIUM Follow us Send me daily emails Advertise With Us Marketing Solutions Finance Jobs Legal Jobs Business Support Jobs Contact Us About Us N
Graduate Hardware Engineer - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search Vivo … Hours: Full time – 35 hours per week Location: On site Application Applications should be sent to [email protected] and include a CV and a cover letter. Find out more about the company at https://magnitudebiosciences.com Deadline: 30 th January 2024 Scroll to Top
Deals - Business news, local news, expert opinion - Business Live birminghampost Load mobile navigation Around The UK West Midlands East Midlands South West North West North East Yorkshire & Humber South East East London Northern Ireland Wales Scotland Expand Sectors Enterprise Professional Services Retail & Consumer Economic Development Tech Commercial Property Manufacturing Ports & Logistics Law Finance Expand Climate Opinion Partner Stories SUBSCRIBE PREMIUM Follow us Send me daily emails Advertise With Us Marketing Solutions Finance Jobs Legal Jobs Business Support Jobs Contact … list set for growth following seven-figure investment Deals London based Growth Fund 1 has announced the investment into The Pharmacist Network Group Bookmark Tyneside civil engineering firm lays groundwork for growth with £2.4m funding deal Deals Following the deal Holystone has created a spin-off business focused on sustainable material recovery Bookmark North East mayor seals agreement with Lloyds Bank to boost region's energy sector Lloyds The North East mayoral authority
Taiwan - Biotech Companies - Careers Page About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact Taiwan - Biotech Companies - Career Pages Patheon Whitby, ON Contract Manufacturing and Development Cleveland, TN Formulated Solutions develops and manufactures topical, liquid, aerosol, and nasal drugs—supporting partners from clinical to full-scale launch Euthymics Biosciences , Assets acquired by Ethismos Research, Nov 2017 GlycoEra Wädenswil, Switzerland Custom Glycan Platform Harpoon Therapeutics , Acquired … on Channel Innovations , Primitive website, no apparent employees. Got $1M SBIR grant in 2013 ADC Biotechnology , Acquired by Sterling Pharma Solutions, Apr 2021; aka ADCBIO Yaupon Therapeutics , Changed Name to Ceptaris Therapeutics Jan 2012 Diag-Nose.io Notting Hill, Australia Chronic Rhinosinusitis diagnostic and treatment platform CerRx , Website down Feb 2021 - May 2021; Company seems inactive, but trial updated on clinicaltrials.gov in 2019   … s Lexington, MA Stereopure oligonucleotides Carigent Therapeutics , Had a grant in 2008. No info for a long time Axis-Shield , Acquired by Alere, Aug 2011 Princeton BioMeditech Monmouth Junction, NJ POC Diagnostics Geistlich Pharma Root, Switzerland Dental/orthopedic bone substitute/tissue regeneration, medical device Seaport, MA Mispro is a contract vivarium organization (CVO) offering a network of full-service vivarium rental facilities for pr … ealth Princeton, NJ Clinical Development Vadovations , No info. 2012 SBIR grant AcelRx Pharmaceuticals , Renamed Talphera, Jan 2024 Pacific PharmaScience , Business filings late, Jan 2023 - Aug 2025 Inform Genomics , Website Gone Nov 2018 Image Analysis Group London, UK Medical Imaging CRO Prasco Laboratories Mason, OH Authorized Generics Sequana Medical Sint-Denijs-Westrem, Belgium Implantable pump systems AntlerA Therapeutics … p;P10 BIOSCIENCES , Believed defunct, Never registered as MA business, had SBIR grant ALBiotek , Acquired by Vaxcell Bio, Jan 2025 Arkios Biodevelopment , Business registration canceled in VA Novacyt Vélizy-Villacoublay, France Diagnostics gel-e Life Sciences , Renamed Medcura, Dec 2019 Argolyn Bioscience , Bankrupt,
Business Development Manager - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search Vi
Society for Laboratory Automation and Screening: SLAS2022 International Conference and Exhibition Please Login Log In APPLIED Home Catalog FAQs Cart (0 items) Log In SLAS2022 International Conference and Exhibition You must log in to register Non-member - $145 Member - $110 Student Member - Free! Lab Member - $110 Continue Already registered? Log in now. Overview Speaker(s) Contents (135) The SLAS2022 course package contains 135 presentations from the following tracks: Keynote Speakers Assay Development and Screening Automation Technologies Micro- and Nano Technologies Advances in Bioanalytics … chers, clinical leaders, as well as industry partners to develop new resources, apply new technology, and ensure that MJFF research priorities reflect and best serve the ultimate needs of patients. Bradford completed his Ph.D. in Neuroscience at University of Texas Southwestern Medical Center, where he applied new approaches in next-generation sequencing to study the activity of DNA-binding transcription factors in gene expression networks. His postdoctoral research focused o … e expression networks. His postdoctoral research focused on the development and application of novel computational genomics strategies in neuroscience to apply “big data” approaches to biological data sets. Bradford also serves as a scientific liaison to the Accelerating Medicines Partnership (AMP-PD), a public-private consortium focused on leveraging strengths of federal, academic, and industry partners to develop shared research tools and resources for the community. In add … was just awarded the Biochemical Society's Industry and Academic Collaboration Award. Josephine Bunch Martin Giera, Ph.D. Head of the Metabolomics Group at the Center for Proteomics and Metabolomics Leiden University Medical Center Martin studied pharmacy in Heidelberg and Munich. He is the head of the Metabolomics group at the Center for Proteomics and Metabolomics at the Leiden University Medical Center (LUMC). He holds a PhD in Pharmaceutical Chemistry obtained from … rom the Ludwig-Maximilians-University in Munich (Germany) . With a postdoctoral fellowship (DAAD stipend), he joined the group of Prof. Hubertus Irth at the VU University Amsterdam. Following a research stay in the laboratory of Prof. Charles Serhan at Harvard Medical School, he moved to the LUMC where he today heads the Metabolomics group. He is
Magnitude Biosciences Ltd | The Org Platform Enrich Pricing Log in Sign up Magnitude Biosciences Ltd 0 followers Magnitude Biosciences is a biotechnology firm combine experience in ageing research, the nematode C. elegans and automation. Industries Biotechnology , Health Care + 1 Employees 1-10 Links Org chart Teams Offices Positions ( 16 ) Unverified Org chart Fozia Saleem Chief Executive Officer 10 Fozia Saleem Collapse Sara Allan Head of Operations 2 David Weinkove Chief Scientific Officer 6 Teams This company has no teams yet Offices This company has no offices yet Related companies Aste
Fozia Saleem - Chief Executive Officer at Magnitude Biosciences Ltd | The Org Platform Enrich Pricing Log in Sign up Magnitude Biosciences Ltd Fozia Saleem Unverified Fozia Saleem Chief Executive Officer Contact Fozia Saleem has over 20 years of work experience in various industries. Fozia is currently the Chief Executive Officer at Magnitude Biosciences Ltd, a position they have held since 2022. Prior to this, Fozia worked at Broughton from 2019 to 2022, where they held multiple roles including Director of Product Development Services and Director of Scientific Affairs & Programme Manag
Visionary CEO of Magnitude Biosciences, Dr. Fozia Saleem is leading the charge in pre-clinical research. Her goal is to become the go-to Contract Research Organisation for screening compounds for the pharmaceutical and nutraceutical industries, using their patented WormGazer™ technology. In a recent interview, Dr Saleem shared her thoughts on the future of biotech. She believes that the sector is poised for significant growth in the coming years, driven by factors such as the increasing prevalence of age-related diseases and the growing demand for personalised medicine. Read the full story her
Fozia Saleem - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platform
David Weinkove about ARDD | Magnitude Biosciences Ltd LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy
Rapid measurement of ageing by automated monitoring of movement of C. elegans populations Rapid measurement of ageing by automated monitoring of movement of C. elegans populations Geroscience . 2024 Apr;46(2):2281-2293. doi: 10.1007/s11357-023-00998-w. Epub 2023 Nov 8. Authors Giulia Zavagno 1 2 , Adelaide Raimundo 2 , Andy Kirby 2 , Christopher Saunter 2 , David Weinkove 3 4 Affiliations 1 Department of Biosciences, Durham University, Stockton Road, Durham, DH1 3LE, UK. 2 Magnitude Biosciences Limited, NETPark Plexus, Th
David Weinkove - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platfo … is passionate about applying the strength of C. elegans research to industrial application and he cofounded the Magnitude Biosciences team to bring reliable automated technology together with experienced C. elegans scientists to bring increases in productivity to the whole field. Back to Team Our Services Ageing & Longevity Microbiome Neurodegeneration Toxicity Transgenics Who we help Nutraceuticals & Ingredients Cosmeceuticals Biotechnology Pharma Academia Why C. el
Chris Saunter - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platfor
Our Team - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platform Wor
Axios - Phoenix is linking research, startups and industry... Facebook Log In Axios's Post Axios Verified account with City of Phoenix, AZ USA Paid Partnership · June 9 at 4:49 AM · Shared with Public Phoenix is linking research, startups and industry into a stronger bioscience pipeline. Content by Phoenix Bioscience Core. axios.com PBC is making Arizona's bioscience ecosystem easier to navigate Learn more All reactions: 7 Like Comment
Lifespan News - A consortium of groups has come together... Facebook Log In Lifespan News's Post Lifespan News February 27, 2019 · Shared with Public A consortium of groups has come together with the painstaking task of charting the longevity industry, such as its companies, journalists, thought leaders, investors, and recent developments. leafscience.org Longevity Industry Report – UK Edition | All reactions: 14 1 comment 19 shares Like Comment Most relevant André Andrade Victória Quiroga 7y
Jobs - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platform WormGaz
#006-YeToTo: Yesterday, Today, Tomorrow | Notion | Pablo Gonzalo Salaverria Izaguirre LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s … (ABFE) in the absence of experimental crystal structures, making it possible to apply gold-standard, physics-based free energy calculations much earlier in the drug discovery process. On Oct. 29, learn more about how Boltz-2 was developed, how it has evolved, and how it is being applied to Recursion’s AI-enabled drug discovery platform at Genetic Engineering & Biotechnology News ’ State of AI in Drug Discovery free virtual event. Najat Khan, PhD , Chief R&D Officer an … ed topics Microfluidic Technology How Organoid Technology Improves Drug Testing Application of Microfluidics in Tissue Engineering Latest Developments in Organoid Technology Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recruitment & HR Customer Experience Real Estate Marketing Sales Retail & Merchandising Science Supply Chain Management Futur
Top 50 Social Media VC Funds & Investors in United Kingdom (June 2026) | Shizune 300+ investors in your industry, stage, and region Get Social Media Any industry Artificial Intelligence Google EdTech Clean Energy Retail Enterprise Software Local Travel Platforms InsurTech Social Impact Oil and Gas Cryptocurrency SaaS Film Restaurants Photography Payments Renewable Energy Organic Food Email Fitness CleanTech Energy Health Care Machine Learning Agriculture (AgTech) Marketplace Gaming Facebook Blockchain Social Network B2B Big Data Video Games Education Wellness Medical Device Mobile Legal Sp … Investor Relevant Deals Geography Stage Focus Round Size Northstar Ventures VC Fund 8 United Kingdom, United States, Indonesia Seed, Series A Software, Health Care, E-Commerce $39k–$9.7M Ascension VC Fund 7 United Kingdom, United States, Italy Seed, Pre-Seed Software, FinTech, Internet $229k–$4.1M Hotspur Capital VC Fund 6 United Kingdom, United States Seed, Angel Mobile, Software, Location Based Services $35k–$1.4M Mercuri VC Fund 5 United Kingdom, United States, Canada See … ries A Artificial Intelligence, Software, Machine Learning $70k–$20M The Future Fund VC Fund 4 United Kingdom, United States, Canada Convertible Note, Seed Software, FinTech, Financial Services $347k–$7.2M Fuel Ventures VC Fund 4 United Kingdom, United States, Ireland Seed, Pre-Seed, Series A Software, SaaS, Information Technology $338k–$20M Maven Capital Partners VC Fund 4 United Kingdom, United States, Germany Seed, Series A Software, Information Technology, SaaS $655k–$25M … Series A Software, Information Technology, SaaS $655k–$25M Supernode Global VC Fund 4 United Kingdom, United States, Germany Seed, Pre-Seed Software, Information Technology, Media and Entertainment $1.5M–$6.8M Avonmore Developments VC Fund 4 United Kingdom, Japan, Canada Seed, Pre-Seed, Series A Software, E-Commerce, Artificial Intelligence $396k–$65M Seedrs VC Fund 3 United Kingdom, United States, Estonia Seed, Equity Crowdfunding, Pre-Seed E-Commerce, Software, Food and Be … owdfunding, Pre-Seed E-Commerce, Software, Food and Beverage $39k–$5M Venrex VC Fund 3 United Kingdom, United States, France Seed, Series A, Pre-Seed E-Commerce, Fashion, Internet $425k–$13M Wayra VC Fund 3 Spain, United Kingdom, United States Seed, Series A Software, Information Technology, SaaS $145k–$15M Notion Capital VC Fund 3 United Kingdom
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
VivoScan™: Abundant Whole-Organism Data for AI-driven Drug Discovery Pipelines - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications B
News Archives - Northstar Ventures ABOUT US FUNDS PORTFOLIO NEWS OUR TEAM CONTACT ABOUT US FUNDS PORTFOLIO NEWS OUR TEAM CONTACT Category: News Northstar Ventures awarded management of £22.5m fund to invest in high potential university spinouts Northstar Ventures has been awarded the management of the £22.5m North East Spinout Inspire Fund. The £22.5m North East Spinout Inspire Fund is backed by the universities of Durham, Newcastle, Northumbria, Sunderland and Teesside, as well as North East Mayor Kim McGuinness and The North East Mayoral Strategic Authority (via the North East Fund). It [&he … ost Northstar Ventures has invested £250,000 via the North East Spinout Inspire Fund in Gnosis Health, to support the development and launch of AI-powered digital healthcare assistant MAXine, designed to transform the management of Parkinson’s disease. The investment forms part of a £570,000 seed round alongside £320,000 from SFC Capital, leveraging a £550,000 Innovate UK investor […] Northstar Ventures Announces Investment into Clean Energy Disruptor H2CHP as Part of … res has announced a £300,000 investment from the new North East Spinout Inspire Fund into H2CHP, a pioneering cleantech company and a spinout of Durham University. The commitment forms part of a round of £1.5m alongside £500,000 from Blackfinch Ventures and £700,000 of grant funding from Innovate UK’s investor partnership programme to develop a […] Northstar Ventures leads £6.5m investment round into revolutionary synthetic DNA pioneer NunaBio Award-winning Newcastle U … funds, including this first investment from the new North East Spinout Inspire Fund, the North Est Innovation Fund and the Northstar EIS Growth Fund. A mix of institutional […] Northstar Ventures opens the third tranche of its EIS Growth Fund for investor subscriptions Northstar Ventures opens the third tranche of its EIS Growth Fund for investor subscriptions Before too long, you could be travelling in a luxury car powered by a next generation electric motor. You cou … ends AI with high […] Venture Sunderland – Why it’s Smart to Base a £16m Fund in the UK’s Smartest City Northstar Ventures has been embedded in the North East’s innovation ecosystem for over twenty years. In 2024, Northstar launched the Venture Sunderland Fund, to back ambitious, scalable businesses at all stages in and around the Sunderla
North East deals of the week: key contracts, investments and acquisitions | Business Live Skip to main content Business Live - UK Business news, analysis & Thought Leadership South West North West North East Wales More Latest from the World Cup 2026 here Send me daily emails Advertise With Us Marketing Solutions Finance Jobs Legal Jobs Business Support Jobs Contact Us Around The UK South West North West North East Wales Yorkshire & Humber West Midlands East Midlands South East East London Northern Ireland Scotland Sectors Enterprise Professional Services Retail & Consumer Comme … 6:32, 31 Jul 2023 Dr Stephan Meeder, CEO and CFO of CropEnergies AG (left) with Grant Pearson, chairman of Ensus UK examining the animal feed currently produced at the Ensus plant. (Image: Ensus) Bioethanol maker Ensus UK revealed plans to invest around £90m into its Teesside operations. The Wilton International firm's German parent company - CropEnergies AG - will invest in a series of projects at the Redcar site - the largest of which will be the creation of a new hi … : “We are delighted to have secured the Innovate UK Biomedical Catalyst R&D grant alongside our superb neighbours and collaborators. These awards come at an important part of our business journey, and I am sure this support will help grow all our companies. The health and life sciences sector presents a huge number of opportunities for the North East and it’s been great to have the support of MP Chi Onwurah and to see the interest and levels of investment benefitting so m … businesses in the region.” Rob Brown of Jump (front) with Mike Guellard of NEL Fund Managers. (Image: NEL Fund Managers) Growing Tyneside digital agency Jump is set to create jobs and build its European presence after securing a six-figure investment. Jump offers creative design, digital solutions and marketing services to a roster of regional, national and international clients, including Newcastle’s Business Improvement District company NE1, the NHS, Newcastle University, … rowth – has now sealed a £100,000 investment from the North East Growth Capital Fund Supported by the European Regional Development Fund, with help from regional fund management firm NEL Fund Managers. Jump will use the investment to fuel expansion of both its North East team and its overall client base, with a view to reaching a £1.2m turnover t
BCI Pharma - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Co
Maven leads investment in Magnitude Biosciences Skip to content Investor Area Seek Investment Overview Management Buyout Growth Capital Regional Growth Funds About Our Regional Funds Finance Durham Fund IFS Maven Equity Finance MEIF II Debt Finance East and South East Midlands NPIF II Maven Equity Finance SWIF Maven Equity Finance Property Invest Overview Private Investor Co-investment About Maven Investor Partners Private Equity Investment Property Investment EIS About EIS Maven Cognition EIS VCTs About VCTs Current Offers Institutional Investor Buyout Fund Portfolio About Our story News Meet … form. Published: May 27, 2025 Focus: NPIF Maven Equity Finance , Finance Durham Fund Magnitude Biosciences, a specialist contract research organisation based in County Durham, has secured over £700,000 to scale its high-throughput screening platform for in vivo discovery of treatments for age-related conditions and other diseases using C. elegans, a species of nematode worms . The investment was led by NPIF II - Maven Equity Finance , which is managed by Maven as part of … aven as part of the British Business Bank's Northern Powerhouse Investment Fund II, and the Finance Durham Fund , established by Durham County Council and overseen by Business Durham, as well as continued support from existing investors NorthStar Ventures. The investment was matched with grant funding from Innovate UK through the Investor Partnerships: Digital Technologies North East programme. This funding will enable Magnitude Biosciences to enhance its proprieta … r the business you advise, is looking for an equity investment as a solution to fund future growth, get in touch here > Posted in: NPIF Maven Equity Finance Finance Durham Fund Subscribe for email updates Maven backs NunaBio through NPIF II Maven Equity Finance Maven strengthens North East team with two new appointments Bdaily secures six-figure investment to fuel national expansion North East businesses benefit from share of £275m as NPIF II mark
#innovation #tech | Magnitude Biosciences Ltd LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Co … . From GSK to Magnitude Biosciences Ltd , and including a sink-or-swim 3-months deadline to get an entirely new product category to market (and being the 1st company to launch it on the UK market), Fozia has been guided by her passion for R&D, outcome-focused #innovation and game-changing #tech . The podcast is available here https://lnkd.in/eqaGgYZW , from Friday 28th November. 🎙️ 37 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 4,603 fol
From R&D to CRO CEO - Molecule to Market: Inside the outsourcing space - Apple Podcasts بحث الرئيسية جديد قوائم الأفضل بحث ٢٨ نوفمبر ٢٠٢٥ ٥٠ د From R&D to CRO CEO Molecule to Market: Inside the outsourcing space تشغيل In this episode of Molecule to Market , you’ll go inside the outsourcing space of the global drug development sector with Dr. Fozia Saleem, Chief Executive Officer at Magnitude Biosciences. Your host, Raman Sehgal, speaks with Fozia about the pharmaceutical and biotechnology supply chain, including: How her early roles shaped her focus on applying science and innovation i
Magnitude Biosciences secures over £700,000 to accelerate in vivo high-throughput drug discovery platform LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … nce that Magnitude Biosciences has secured over £700,000 in combined equity and grant funding to scale up our proprietary high-throughput screening (HTS) platform. The investment was led by Maven North East with continued support from Northstar Ventures , and matched grant funding from Innovate UK under the Investor Partnerships: Digital Technologies North East programme. This funding will enable us to enhance our proprietary WormGazer® technology, integrating robotics, machi
Magnitude Biosciences CEO Acknowledged as a Game-Changing Industry Leader | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subsc … sting. In June 2023, the company secured a Future Economy Investor Partnerships grant of almost £250,000 from Innovate UK, which was matched by an investment from the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures Limited. Dr. Saleem said the funding is helping to accelerate research and growth. “As scientists and institutes increasingly look to improve the population’s healthspan –
--> Upcoming Podcast Spotlight: Magnitude Biosciences Takes Molecules to Market top of page About NETPark NETPark People NETPark Companies Total Support Environment Funding & Finance Community Engagement Collaborative Networks Success Stories Locate Here Available Space Phase Three NETPark Plexus NETPark Explorer NETPark Discovery Meeting Rooms NETPark Virtual Office Services & Facilities Centre For Process Innovation (CPI) National Formulation Centre High Value Manufacturing Catapult Compound Semiconductor Apps Catapult Durham University Research Institute National Healthcare Photonic … by real-world challenge and innovation — including a sink-or-swim, three-month deadline to bring an entirely new product category to market, becoming the first company to launch it in the UK. What drives her forward? A consistent passion for R&D, outcome-focused innovation, and game-changing technology that pushes scientific boundaries. Listeners can expect candid reflections on leadership, vision, and seeing “the bigger picture” — or as Fozia puts it, “getting into your
Resource Hub - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platform … sortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases AB Biotek works with Magnitude Biosciences to accelerate probiotic development Case Study: AB Biotek works with Magnitude Biosciences to accelerate probiotic development Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative … to support continued growth Magnitude Biosciences secures UK government Future Fund to expand its workforce Magnitude Biosciences’ new COVID-19 compatible laboratory is fully operational and ready to support research Magnitude Biosciences will be presenting at the online European Worm Meeting Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd. Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham Univer
Scaling for Success Ep 1: Dr Fozia Saleem, CEO of specialist Contract Research Organisation, Magnitude Biosciences - Invested | Podcast on Spotify
@dweinkove.bsky.social on Bluesky JavaScript Required This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is. Learn more about Bluesky at bsky.social and atproto.com . Profile David Weinkove dweinkove.bsky.social did:plc:mj3rfybzwhdyfp7a7u6bkxqk Biology of ageing. How bacteria age us. Prof at Durham Uni, Chair of British Society for Research on Ageing and CSO, Magnitude Biosciences. Love C. elegans.
Magnitude Biosciences Podcast Ep 1 | Dr Alex Parker: Screening probiotics to treat ALS with C. elegans - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studi
Case Study: AB Biotek works with Magnitude Biosciences to accelerate probiotic development - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Pu
https://lnkd.in/etaE-QXg #CountyDurham #NorthEast #NETPark #DurhamUniversity #Collaboration"> https://lnkd.in/etaE-QXg #CountyDurham #NorthEast #NETPark #DurhamUniversity #Collaboration"> https://lnkd.in/etaE-QXg #CountyDurham #NorthEast #NETPark #DurhamUniversity #Collaboration"> Durham University spinout Magnitude Biosciences gains global recognition | Business Durham posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including profes
https://lnkd.in/e2uM5_mn #NETPark #DurhamUniversity #Collaboration #BusinessGrowth #STEM"> https://lnkd.in/e2uM5_mn #NETPark #DurhamUniversity #Collaboration #BusinessGrowth #STEM"> https://lnkd.in/e2uM5_mn #NETPark #DurhamUniversity #Collaboration #BusinessGrowth #STEM"> Durham University spinout gains global recognition for worm-based drug discovery | The North East Technology Park - NETPark posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you releva … Report this post **Virginia Tech's Discovery Lab: Bridging Theory and Practical Application** Virginia Tech's new Discovery Lab is a bold step towards integrating hands-on research with academic learning. This initiative not only empowers undergraduates with essential skills but also fosters innovation through peer-led projects in cutting-edge fields like biosensors and microp. At ElevenX Capital, we believe that investing in educational infrastructure like this is crucial fo
Invermis - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners Tu
Why C. elegans? | C. elegans as a Model Organism | Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search f … and amenability to modification Verified use as a natural ageing model Valuable application in drug discovery candidate screening Established use in nutritional studies and bioactive ingredients testing Intrinsic host-microbe interaction, so can easily be raised germ-free Easy transgenic expression for models of human diseases Existing mutant and transgenic strains available for research Our Services Ageing & Longevity Microbiome Neurodegeneration Toxicity Transgenics Who
Anti-ageing research company secures investment - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbio … 500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures, and Saker Capital. The company’s earlier loans totalling £250,000 from the Coronavirus Future Fund (UK FF Nominees Limited), Saker Capital and Northstar Ventures have also been converted as part of this investment round. This new funding will enable Magnitude to expand its research faci
Publications - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platform
“In a week, we can tell if something slows aging” – Magnitude Biosciences CEO Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search DiamiR, AlzLabs
Technology Networks: Addressing Key Limitations in Disease Models - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News
Neurodegeneration | C. elegans for Neurodegeneration Testing | Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Cont
Magnitude Biosciences Named Innovate UK Finalist | Maven North East posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … rted the business through NPIF II - Maven Equity Finance and the Finance Durham Fund, backing the development of its next-generation WormGazer drug screening platform. 💊 This recognition reflects the businesses continued commitment to advancing the future of ethical, early-stage drug discovery. Learn more about Magnitude👇 https://lnkd.in/eV3nyDJN #NorthEast #DrugDiscovery | British Business Bank North of England | Business Durham 30 1 Comment Like Comment Share Copy LinkedI … the past week, one Biotech related, one sport related: JEITO announced its new fund - over €1bn - a record for a European Life Science focused fund, reinforcing its commitment to backing innovative biotech companies and accelerating the next generation of breakthrough therapies. The market has been tough in the past few years but this is a strong signal of confidence in European led science and innovation. Meanwhile, Rory McIlroy delivered once again at Augusta, retaining hi … and many others. American Association for Cancer Research 87,502 followers 2mo Submit an abstract by May 7 for the AACR D3 Conference on Drug Discovery and Development (July 21-24; Boston), chaired by AACR President Lillian L. Siu, Patricia M. LoRusso, Keith T. Flaherty, and Timothy A. Yap. Learn more: https://brnw.ch/21x1CTN #AACRdrugdev26 59 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in EdgeOne Medical 2,648 followers 2mo Report this post Ma
Home - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ Case Studies Videos Publications Brochures News Contact Search for: Search Search VivoScan™ Platform WormGaz
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and ready to support research - Magnitude Biosciences Skip to content VivoScan™ Platform WormGazer™ Technology Our Assays Healthy Ageing & Longevity Gut Health Muscle Health Cognitive Health Weight Management Neurodegeneration Manual Paralysis Toxicity Transgenics Rapamycin Company About Us Why C. elegans? Our Team Who we help Health & Nutrition Nutraceuticals & Ingredients Microbiome Cosmeceuticals Biotechnology Pharma Ageing & Longevity Academia Testimonials Jobs Resources All Resources FAQ